Galapagos completes transfer of Jyseleca business to Alfasigma

As previously announced, the transfer includes the entire Jyseleca business, including the European and UK Marketing Authorizations, and the commercial, medical affairs and development activities for Jyseleca . In connection with the completion of the transaction, approximately 400 Galapagos positions in 14 European countries transferred to Alfasigma to support business continuity and ongoing patient access “We are excited to welcome the talented Galapagos team to Alfasigma. The acquisition of Galapagos’ Jyseleca business, including a Phase 3 clinical program, strategically strengthens our position in the pharmaceutical sector and opens new avenues for growth and innovation. We are ready to expand and harness the synergies of Alfasigma and Jyseleca and we look forward to working with our new colleagues to further expand our healthcare business in Europe.” Galapagos will receive a EUR 50M upfront payment, potential sales-based milestone payments totaling EUR 120M and mid-single to mid-double-digit royalties on European sales. Galapagos will contribute up to EUR 40 million to Alfasigma by June 2025 for Jyseleca related development activities. Galapagos expects to realize substantial savings ranging between EUR 150 M and EUR 200 M in connection with the transaction and will prioritize investments in its existing technology platforms of small molecules, CAR-T cell therapies and biologics, as well as the scale-up of its innovative decentralized CAR-T manufacturing network. In addition, Galapagos plans to invest in licensing and acquisition opportunities ranging from late preclinical to mid-stage clinical assets in its strategic therapeutic areas to drive value across its pipeline.